- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05830773
Resonance Breathing Intervention Opioid Use Disorder
January 8, 2024 updated by: Fiona Conway, University of Texas at Austin
Resonance Breathing Opioid Use Disorder
This study aims to assess the feasibility of an intervention for the management of craving, stress, anxiety, and depression among people who use opioids via a resonance breathing smartphone app.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Most evidence-based treatments for substance use disorders (SUD) require face-to-face interactions with individuals who comprise a recovery support network.
However, in the moment relapse occurs, people in recovery are often not in the presence of these trusted individuals.
This project aims to address this issue by providing people in recovery with an application (app) that can be added to phones and other mobile devices to help them manage cravings, anxiety, and stress triggers at the specific moments they feel compelled to use.
The connection between an individuals mind and body works in both directions.
Psychological distress can cause psychosomatic symptoms in the body (e.g., stress is related to multiple chronic health conditions), but individuals can also use their bodies to affect psychology aspects (e.g., exercise can improve mood by releasing endorphins).
A similar scientific theory is the foundation of controlled breathing interventions for anxiety, stress, and drug cravings.
Psychological distress can disrupt the balance of our Autonomic Nervous System (which is responsible for our fight or flight response to threat), but breathing exercises can restore balance and decrease stress.
The goal of this study is to test the feasibility, utility, and efficacy of an app that delivers controlled breathing exercises.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- Online
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
To be eligible, participants need to be the legal age of majority (18 years of age or older), have the ability to read and speak in English, and have a history of alcohol or illicit drug use.
Exclusion Criteria:
Individuals with no access to a smartphone phone with a data plan, inability to provide consent and having suicidal thoughts or psychotic episodes.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: App Trial
Use of the smartphone app
|
This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices.
The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate.
PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation.
The app also has a timer (to allow the participant to see how long they use the app in each session).
The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale).
Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average rating of participant satisfaction with the app as assessed by the Acceptability of Intervention Measure
Time Frame: 8 weeks
|
The measure has 4 items on a scale from 1 (completely disagree) to 5 (completely agree).
Higher scores are better outcomes.
The citation for the measure is Weiner BJ, Lewis CC, Stanick C, et al.
Psychometric assessment of three newly developed implementation outcome measures.
Implement Sci 2017; 12(1):108.
|
8 weeks
|
Average rating of participant assessment that the app is appropriate for managing cravings, stress, and anxiety as assessed by the Intervention Appropriateness Measure
Time Frame: 8 weeks
|
The measure has 4 items on a scale from 1 (completely disagree) to 5 (completely agree).
Higher scores are better outcomes.
The citation for the measure is Weiner BJ, Lewis CC, Stanick C, et al.
Psychometric assessment of three newly developed implementation outcome measures.
Implement Sci 2017; 12(1):108.
|
8 weeks
|
Average rating of participant assessment of whether the app was easy and practical to use as assessed by the Feasibility of Intervention Measure.
Time Frame: 8 weeks
|
Feasibility entails participant assessment of whether the app was easy and practical to use.
The measure has 4 items on a scale from 1 (completely disagree) to 5 (completely agree).
Higher scores are better outcomes.
The citation for the measure is Weiner BJ, Lewis CC, Stanick C, et al.
Psychometric assessment of three newly developed implementation outcome measures.
Implement Sci 2017; 12(1):108.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average rating of participant assessment of their frequency of drug craving as assessed by the Aggregated Drug Craving Scale.
Time Frame: 8 weeks
|
The measure has 5 items on a scale from 0 (Never - 0 times over the past month) to 6 (Nearly all of the time - more than 40 times or more than 6 times per day).
Lower scores are better outcomes.
The citation for the measure is: Costello MJ, Viel C, Li Y, Oshri A, MacKillop J. Psychometric validation of an adaptation of the Penn Alcohol Craving Scale to assess aggregated drug craving.
J Subst Abuse Treat 2020; 119:108127.
|
8 weeks
|
Average rating of participant assessment of their frequency of experieincing stress as assessed by the Peceived Stress Scale.
Time Frame: 8 weeks
|
The measure has 10 items on a scale from 0 (Never) to 4 (Very Often).
Lower scores a better outcomes.
The citation for the measure is: Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.
Journal of health and social behavior.
1983 Dec 1:385-96.
|
8 weeks
|
Average rating of participant assessment of their frequency of experieincing anxiety as measured by the Beck Anxiety Inventory.
Time Frame: 8 weeks
|
The measure has 21 items on a scale from 0 (Not at all) to 4 (Severely).
Lower scores are better outcomes.
The citation for the measure is: Beck AT, Epstein N, Brown G, Steer RA.
An inventory for measuring clinical anxiety: psychometric properties.
J Consult Clin Psychol 1988; 56(6):893-7.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fiona Conway, PhD, The University of Texas at Austin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
- Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3.
- Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7. doi: 10.1037//0022-006x.56.6.893. No abstract available.
- Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.
- Vafaie N, Kober H. Association of Drug Cues and Craving With Drug Use and Relapse: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022 Jul 1;79(7):641-650. doi: 10.1001/jamapsychiatry.2022.1240.
- Kennedy AP, Epstein DH, Jobes ML, Agage D, Tyburski M, Phillips KA, Ali AA, Bari R, Hossain SM, Hovsepian K, Rahman MM, Ertin E, Kumar S, Preston KL. Continuous in-the-field measurement of heart rate: Correlates of drug use, craving, stress, and mood in polydrug users. Drug Alcohol Depend. 2015 Jun 1;151:159-66. doi: 10.1016/j.drugalcdep.2015.03.024. Epub 2015 Apr 7.
- Price JL, Bates ME, Morgano J, Todaro S, Uhouse SG, Vaschillo E, Vaschillo B, Pawlak A, Buckman JF. Effects of arousal modulation via resonance breathing on craving and affect in women with substance use disorder. Addict Behav. 2022 Apr;127:107207. doi: 10.1016/j.addbeh.2021.107207. Epub 2021 Dec 17.
- Brzozowski A, White RG, Mitchell IJ, Beech AR, Gillespie SM. A feasibility trial of an instructed breathing course in prison to improve emotion regulation in people with substance use difficulties. The Journal of Forensic Psychiatry & Psychology 2020; 32(2):308-25.
- Costello MJ, Viel C, Li Y, Oshri A, MacKillop J. Psychometric validation of an adaptation of the Penn Alcohol Craving Scale to assess aggregated drug craving. J Subst Abuse Treat. 2020 Dec;119:108127. doi: 10.1016/j.jsat.2020.108127. Epub 2020 Sep 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2021
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
March 30, 2023
First Submitted That Met QC Criteria
April 13, 2023
First Posted (Actual)
April 26, 2023
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
January 8, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000590
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No individual participant data (IPD) will be shared
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
VA Office of Research and DevelopmentRecruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Resonance Breathing Exercises
-
Derya AzimCompletedStroke | Physiotherapy and RehabilitationTurkey
-
Uppsala UniversityThe Swedish Research Council; Örebro County CouncilCompleted
-
Riphah International UniversityCompleted
-
Hasan Kalyoncu UniversityCompletedChronic Low-back PainTurkey
-
Federal University of BahiaCompletedParkinson Disease | DysphagiaBrazil
-
Foundation University IslamabadRecruiting
-
Naestved HospitalRecruiting
-
Riphah International UniversityCompleted
-
Golden Jubilee National HospitalCompletedCoronary Artery Disease | Lung Cancer | Lung TumorUnited Kingdom
-
Riphah International UniversityRecruiting